News
-
-
PRESS RELEASE
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
CAGE Bio initiates Phase 2b trial for CGB-500, a topical JAK inhibitor ointment for atopic dermatitis. High efficacy, low side-effects. Improving patient outcomes -